302440.KO SK Bioscience Co Ltd
- Market cap
- KRW 2.90T
- P/E
- -
- P/B
- 1.55x
- ROE
- -5.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 302440.KO undervalued?
Graham numberThe Graham number of SK Bioscience Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SK Bioscience Co Ltd fundamental analysis
No fundamental analysis for SK Bioscience Co Ltd yet.
SK Bioscience Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the devel…
Full company profileSK Bioscience Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SK Bioscience Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 88.2B | 184B | 226B | 929B | 457B | 370B | 268B | 651B | 649B |
| Gross Profit | 39.2B | 79.6B | 95.3B | 570B | 240B | 142B | 31.0B | 75.9B | 113B |
| Operating Income | 15.2B | 6.47B | 37.7B | 474B | 115B | -12.0B | -138B | -124B | -121B |
| EBITDA | 9.88B | 37.2B | 58.0B | 493B | 171B | 43.5B | -36.2B | 14.6B | -12.8B |
| Net Income | 421M | 14.7B | 32.9B | 355B | 122B | 22.3B | -53.9B | -57.4B | -102B |
| EPS | 6.88 | 240 | 537 | 4,642 | 1,595 | 290 | -701 | -732 | -1,306 |
| Balance Sheet | |||||||||
| Total Assets | 403B | 404B | 562B | 2.11T | 2.14T | 1.85T | 2.84T | 2.96T | 2.98T |
| Total Liabilities | 192B | 171B | 298B | 509B | 400B | 149B | 821B | 918B | 975B |
| Shareholders' Equity | 211B | 233B | 264B | 1.60T | 1.74T | 1.70T | 1.80T | 1.79T | 1.75T |
| Cash & Short-term Investments | 4.49B | 14.4B | 25.0B | 98.0B | 225B | 127B | 313B | 106B | 130B |
| Cash Flow | |||||||||
| Operating Cash Flow | 14.9B | 21.8B | 120B | 537B | -125B | 29.3B | -128B | 103B | -79.7B |
| Capital Expenditure | 6.31B | 24.0B | 9.93B | 42.9B | 76.5B | 50.3B | 172B | 260B | 268B |
| Free Cash Flow | 8.59B | -4.04B | 110B | 492B | -201B | -20.9B | -300B | -158B | -348B |
| Ratios | |||||||||
| ROE | 0.2% | 6.3% | 12.5% | 22.2% | 7.0% | 1.3% | -3.0% | -3.2% | -5.9% |
| ROA | 0.1% | 3.6% | 5.8% | 16.8% | 5.7% | 1.2% | -1.9% | -1.9% | -3.4% |
| Net Profit Margin | 0.5% | 8.0% | 14.6% | 38.2% | 26.8% | 6.0% | -20.1% | -8.8% | -15.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SK Bioscience Co Ltd dividends
SK Bioscience Co Ltd has not paid dividends in the last 8 fiscal years.
Who owns SK Bioscience Co Ltd
- Insiders 68.69%
- Institutions 3.38%
- Public & others 27.93%
- Shares outstanding 78.5M
- Free float 25.6M
SK Bioscience Co Ltd company profile
- Company name
- SK Bioscience Co Ltd
- Ticker
- 302440.KO
- ISIN
- KR7302440003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 917
- Fiscal year end
- December
- Address
- 310, Pangyo-ro, Seongnam-si, South Korea, 13494
- Phone
- 82 2 2008 2200
- Website
- skbioscience.co.kr
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.
SK Bioscience Co Ltd management
5- Mr. Jae-Yong AhnCEO, President & Director · born 1967
- Dr. Sally ChoeHead of Global Clinical Development & Regulatory Affairs
- Ki-seok SongValue Innovation Director · born 1970
- Jin-seon ParkHead of Marketing & Business Development · born 1973
- Jung-seok LeeRegistered Executive